Enliven Therapeutics
ELVN
32 hedge funds and large institutions have $228M invested in Enliven Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 4 closing their positions.
0.38% more ownership
Funds ownership: 15.82% → 16.2% (+0.38%)
6% less funds holding
Funds holding: 34 → 32 (-2)
24% less capital invested
Capital invested by funds: $302M → $228M (-$73.7M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.5M |
| 2 |
DM
Deerfield Management
New York
|
+$2.11M |
| 3 |
State Street
Boston,
Massachusetts
|
+$174K |
| 4 |
SG Americas Securities
New York
|
+$148K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.1M |
| 2 |
Jane Street
New York
|
-$314K |
| 3 |
Millennium Management
New York
|
-$306K |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$220K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$170K |
ELVN Hedge Fund Activity: Q3 2020 in Review
32 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2020, worth a combined $228M — down 24% from $302M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ELVN and 2 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was Fidelity Investments, adding an estimated $18.5M. The largest seller was RA Capital Management, cutting an estimated $13.1M.
- 32 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2020, down from 34 in Q2 2020.
- Funds reported $228M of Enliven Therapeutics stock for Q3 2020, down 24% quarter-over-quarter.
- 2 funds opened new Enliven Therapeutics positions in Q3 2020 and 4 closed out, a net change of -2 holders.
- The largest Enliven Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $18.5M added.
- The largest Enliven Therapeutics seller in Q3 2020 was RA Capital Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2020.